Cited 0 times in
PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.